| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Centre for the Study of Liver Disease; Departments of 2 Surgery, 3 Anatomy, and 4 Pathology; 5 Institute of Molecular Biology, The University of Hong Kong, Pokfulam, Hong Kong, China; and 6 Department of Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
Requests for reprints: Kwan Man, Department of Surgery, The University of Hong Kong, L9-55, Faculty of Medicine Building, 21 Sassoon Road, Hong Kong. Phone: 852-2819-9646; Fax: 852-2819-9634; E-mail: kwanman{at}hkucc.hku.hk.
Purpose: Recurrence after resection and metastasis are common in hepatocellular carcinoma and are associated with poor prognosis. Therefore, effective treatment is urgently needed for improvement of patients' survival. Previously, we reported that FTY720 has an antimetastatic effect on hepatocellular carcinoma cell line through down-regulation of Rac signaling pathway. This study aims to investigate the in vivo antimetastatic potential of FTY720 in an orthotopic nude mice model using metastatic human hepatocellular carcinoma cell lines MHCC-97L (lower metastatic potential) and MHCC-97H (higher metastatic potential).
Experimental Design: The nude mice bearing liver tumors were randomized into a treatment group and a control group, each with 12 mice. FTY720 was administered at a dosage of 5 or 10 mg/kg via i.p. injection after 7 days of tumor inoculation. Thirty-five days later, the mice were sacrificed for record of intrahepatic and pulmonary metastases.
Results: After 35 days of FTY720 treatment at the dosages of 5 and 10 mg/kg, all 12 mice in the treatment group were alive and well. FTY720 at the dosages of 5 and 10 mg/kg significantly suppressed the tumor volume and intrahepatic and pulmonary metastases in the metastatic nude mice model. FTY720 suppressed intrahepatic and pulmonary metastases by inhibition of Rac expression, which at least in part down-regulated the vascular endothelial growth factor expression and CD34 staining in a dose-dependent manner.
Conclusion: FTY720 is a promising novel therapeutic drug for treatment of hepatocellular carcinoma metastasis.
This article has been cited by other articles:
|
|
 |
|
  X. Ye Lysophospholipid signaling in the function and pathology of the reproductive system Hum. Reprod. Update, September 1, 2008; 14(5): 519 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhong, Y.-J. Wen, H.-S. Yang, H. Luo, A.-F. Fu, F. Yang, L.-J. Chen, X. Chen, X.-R. Qi, H.-G. Lin, et al. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice Ann. Onc., September 1, 2008; 19(9): 1584 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Espina, M. V. Cespedes, M. A. Garcia-Cabezas, M. T. G. del Pulgar, A. Boluda, L. G. Oroz, P. Cejas, M. Nistal, R. Mangues, and J. C. Lacal A Critical Role for Rac1 in Tumor Progression of Human Colorectal Adenocarcinoma Cells Am. J. Pathol., January 1, 2008; 172(1): 156 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu, X. Zhao, F. Frissora, Y. Ma, R. Santhanam, D. Jarjoura, A. Lehman, D. Perrotti, C.-S. Chen, J. T. Dalton, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma Blood, January 1, 2008; 111(1): 275 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Tian, C. Zhao, J. Ren, Z.-M. Ma, Y.-H. Xie, and Y.-M. Wen Gene-expression profiles of a hepatitis B small surface antigen-secreting cell line reveal upregulation of lymphoid enhancer-binding factor 1 J. Gen. Virol., November 1, 2007; 88(11): 2966 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Lee, R. T.P. Poon, J. Y. Wo, S. Ma, X.-Y. Guan, J. N. Myers, P. Altevogt, and A. P.W. Yuen Lupeol Suppresses Cisplatin-Induced Nuclear Factor-{kappa}B Activation in Head and Neck Squamous Cell Carcinoma and Inhibits Local Invasion and Nodal Metastasis in an Orthotopic Nude Mouse Model Cancer Res., September 15, 2007; 67(18): 8800 - 8809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Murph, T. Tanaka, S. Liu, and G. B. Mills Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in Cancer. Clin. Cancer Res., November 15, 2006; 12(22): 6598 - 6602. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
